Phone
(630) 426-1472
info@corepeptidesbuyusa.com
Address
5401 S Kirkman Rd suite 310, Orlando FL 32819
(630) 426-1472
info@corepeptidesbuyusa.com
5401 S Kirkman Rd suite 310, Orlando FL 32819
$118.00
Follistatin-344 peptide is a synthetic version of the naturally occurring FST344 isoform, widely studied for its role in activin binding and interactions within the TGF-β signaling family. Popular in research focused on myostatin, cellular regulation, and growth factor pathways, this high-quality peptide is valued for its strong scientific relevance and reliable research appeal. Intended for laboratory research use only.
Size: 1mg
Contents: Follistatin-344 (1mg)
Form: Lyophilized powder
Purity: >99%
SKU: P-FOLLISTN-1
Follistatin-344 peptide is a synthetic form of the naturally occurring Follistatin-344 isoform, a glycoprotein widely studied for its role in cellular signaling, protein binding, and regulatory activity across multiple tissue types. In research settings, Follistatin-344 attracts strong interest because it is considered the predominant follistatin isoform expressed in many tissues and is frequently discussed in connection with activin, myostatin, and other members of the TGF-β superfamily. For laboratories and research buyers seeking a high-interest peptide with strong scientific relevance, Follistatin-344 remains a leading option due to its broad research value, consistent demand, and competitive positioning.
Follistatin-344 is a synthetic version of the endogenous FST344 isoform, one of the two primary follistatin variants produced through alternative mRNA splicing. The two best-known isoforms are FST317 and FST344, named according to the precursor molecules from which they are derived. Among these, Follistatin-344 is regarded as the dominant isoform in most tissues, while FST317 is generally thought to represent only a small portion of total encoded mRNA expression. This makes Follistatin-344 especially important in scientific discussions focused on follistatin biology, tissue signaling, and protein interaction research.
Structurally, follistatin is notable for its highly organized domain composition. The protein contains a core N-terminal region and three follistatin domains, commonly referred to as FSD1, FSD2, and FSD3. These domains are defined by conserved cysteine residues that contribute to the stability and binding properties of the molecule. The synthetic Follistatin-344 peptide is designed to reflect the essential structural characteristics of the naturally occurring isoform, making it relevant for researchers exploring protein behavior, signaling pathways, and binding interactions in controlled laboratory environments. You may also be interested in our related research peptides, including Tripeptide, Sermorelin Peptide, Hexarelin, Melanotan 1, Oxytocin Peptide, Snap 8 Peptide, Pinealon, Kisspeptin 10 mg, VIP Peptide, and ARA 290 Peptide.
Because follistatin is naturally present in many tissues, it is often described as an autocrine-associated signaling molecule, meaning it may participate in local cellular communication by interacting with receptors and influencing nearby cell behavior. This broad biological presence is one reason why Follistatin-344 continues to be studied across a range of scientific fields. Interest in this peptide extends beyond a single function, as it is connected to reproductive biology, tissue development, signaling regulation, and growth factor research. For eCommerce stores targeting peptide researchers, highlighting the scientific importance of Follistatin-344 in a clear and natural way can improve both user engagement and organic visibility.
One of the main reasons researchers study Follistatin-344 peptide is its reported ability to bind activin. Activin is involved in a variety of biological signaling processes and is frequently discussed in relation to reproductive function and hormone regulation. In scientific literature, follistatin is commonly described as an activin-binding protein that may reduce or modulate activin activity. This relationship has made Follistatin-344 particularly relevant in studies involving follicle-stimulating hormone, ovarian signaling, gonadal biology, and local endocrine communication. Researchers have suggested that follistatin may be produced in areas such as the pituitary gland, testes, ovaries, and other tissues, supporting the idea that its function may be both local and system-wide.
Follistatin-344 is also of interest because of its potential interactions with proteins in the Transforming Growth Factor-beta, or TGF-β, superfamily. This group includes several important signaling proteins involved in cellular growth, differentiation, and developmental regulation. Among the proteins often discussed alongside Follistatin-344 are Bone Morphogenetic Proteins, or BMPs, which are linked to developmental and structural biological processes. Investigators have also examined possible relationships between Follistatin-344 and Growth Differentiation Factor 9, or GDF9, especially in the context of ovarian follicle development and reproductive signaling.
Perhaps the most widely recognized area of interest involves Growth Differentiation Factor 8, also known as myostatin. Myostatin is known as a regulatory protein associated with muscle cell growth and differentiation. Because follistatin is believed to bind to myostatin, Follistatin-344 has become a notable subject in research focused on myostatin signaling pathways and growth regulation. It is important, however, to present this topic carefully and accurately. Rather than making direct performance claims, a strong SEO product description should frame Follistatin-344 as a peptide studied for its potential role in modulating signaling pathways related to activin and myostatin. This kind of wording supports credibility, protects compliance, and aligns better with how informed buyers search for peptide products online.
Follistatin-344 peptide stands out in the research peptide category because it combines strong scientific relevance with broad search demand. Buyers looking for Follistatin-344 often want more than a short technical label. They are searching for a product page that clearly explains what the peptide is, why it matters, and which biological pathways make it noteworthy. A well-written description helps build trust, improves on-page SEO, and increases the chance of ranking for terms such as “Follistatin-344 peptide,” “Follistatin 344 for research,” “Follistatin myostatin research peptide,” and similar long-tail keywords.
From a commercial perspective, Follistatin-344 fits well into a premium research catalog because it appeals to a knowledgeable audience while still offering strong keyword potential. A quality-focused listing should emphasize scientific relevance, clear product identification, research-only positioning, and dependable value. If your store competes on both quality and price, this is also a good place to reinforce that the product is offered at a competitive price without sacrificing professional presentation. Phrases such as “high-quality research peptide,” “carefully presented for laboratory use,” and “competitive value for research buyers” can help strengthen conversion intent while keeping the tone natural and credible.
For best results, your product page should also include a concise specification block, a research-use disclaimer, and metadata that reflects real buyer search behavior. This creates a stronger SEO foundation while making the page easier to scan for both users and search engines. When written in a natural style, Follistatin-344 content can support rankings, reduce bounce rates, and improve the overall authority of your peptide category pages.
Research Use Notice: Intended for laboratory and research purposes only. Not for human consumption, medical use, or therapeutic application.
Molecular Formula: N/A
Molecular Weight: 3780 g/mol
Other Known Titles: Activin-Binding Protein, FSH-Suppressing Protein, FST
Myostatin is a protein considered to be synthesized by muscle cells, hindering muscle cell differentiation and growth. As mentioned, myostatin protein belongs to the transforming growth factor-beta (TGF-beta) protein, which Follistatin may inhibit. During one 1997 study,(5) it was suggested that mice given Follistatin-344 exhibited reduced levels of myostatin, which might have led to the improved skeletal muscle mass with each mouse weighing 2 to 3 times more than usual, and the increase in mass appeared to result from a combination of muscle cell hyperplasia and hypertrophy.
In another study,(6) Follistatin-344 was induced in mice via a nanoparticle-mediated mode of delivery of mRNA in the liver. The researchers reported that the mRNA messenger appeared to stimulate the hepatic liver cells to naturally synthesize and secrete Follistatin. Results of this study suggested that the peptide mice, given this mRNA-containing nanoparticle, exhibited apparently increased serum levels of Follistatin within three days as compared to the levels in control mice.
The research posits that Follistatin mRNA is translated in the liver, leading to increased serum levels of Follistatin. This elevation in Follistatin was suggested to persist for up to 72 hours post-presentation and was associated with decreased serum concentrations of myostatin and activin A. Activin A is a protein considered to be involved in a myriad of biological processes. It is a member of the transforming growth factor-beta (TGF-β) superfamily. It appears to play significant roles in regulating various cellular functions such as proliferation, differentiation, and apoptosis in numerous cell types. In the context of muscle physiology, activin A is particularly noteworthy for its role in muscle metabolism and remodeling. It is thought to be a critical regulator of muscle mass, as it appears to negatively influence muscle growth by promoting catabolic pathways that lead to muscle atrophy. This action is mediated primarily through its interaction with the activin type IIB receptor (ActRIIB) on muscle cells. Upon binding to this receptor, activin A activates intracellular signaling pathways that increase muscle protein breakdown and inhibit muscle protein synthesis. After 8 weeks of continuous peptide presentation, the lean muscle mass of the peptide mice was reportedly 10% more than the control mice.
In contrast to experiments targeting myostatin such as anti-myostatin antibodies Follistatin offers a broader research approach by also antagonizing activin A. Myostatin-specific experiments primarily focus on inhibiting pathways that directly limit muscle growth, thus promoting hypertrophy. However, they might not address other pathways that contribute to muscle loss, such as fibrosis or inflammation, which are influenced by activin A. Follistatin’s dual antagonistic action might lead to more comprehensive impact in muscle dystrophy models. By inhibiting both myostatin and activin A, Follistatin may not only enhance muscle mass but also reduce muscle stiffness and weakness associated with fibrotic changes. This potential dual action is particularly advantageous because it may address both the loss of muscle mass and the quality of the remaining muscle tissue, potentially leading to improvements in muscle function and strength that surpass those achieved by solely blocking myostatin.(7)
Breast Cancer Cells
Through reverse transcription polymerase chain reaction study (RT-PCR), researchers suggested that Follistatin levels may fluctuate in animal models of breast cancer.(8) One study(9) examined the available gene expression data of mice with breast cancer. In most cases, Follistatin was reportedly under-expressed in carcinogenic breast cells, possibly leading to the increased spread of cancer cells caused by activin proteins. As Follistatin is suggested to bind to and inhibit activin proteins, it was further posited by the researchers that restoring Follistatin in these mice might prevent the prognosis of activin-induced metastasis and improve overall survival.
Esophageal Cancer Cells
Research suggests that bone morphogenic protein (BMP) is one of the causative factors in the transition of normal esophageal tissue to cancerous tissues. Follistatin, speculated to host the capacity to bind and neutralize activin and myostatin, may also interact with BMPs. By modulating the activity of BMP, Follistatin may serve a protective role against the over-proliferation of cellular pathways often seen in cancerous tissues. Experimental studies in Follistatin-344 suggest that the peptide may counteract acid reflux actions, thereby possibly preventing an over-activation of BMP and the development of esophageal cancer cells. More specifically, Follistatin’s potential to inhibit BMP might theoretically prevent the initial steps required for the transformation of normal tissue into cancerous tissue, particularly in environments exacerbated by chronic inflammation or external insults like acid reflux.(10)
There is an odd contrast in the working of Follistatin: it may potentially inhibit metastasis, as well as possibly promote cell proliferation. This is why the peptide is researched in studies scrutinizing increased tumor growth (tumorigenesis) and metastasis.(12) Research has suggested that hepatocytes (i.e., liver cells) may require Follistatin to proliferate. When studied in experimental rats, it was reported by the researchers that the inactivation of activin by Follistatin-344 may be a precondition for cell proliferation to occur. They believed there might be some energy exchange amongst the cells where the energy used for cell migration is shut off to switch with cellular growth and proliferation.
One study(13) was conducted to determine the potential of Follistatin on early liver fibrosis. In this study, rats were divided into one control group and one Follistatin-exposed group for a period of four weeks. Researchers reported that the peptide group showed a 32% decrease in liver fibrosis compared to the control group. They further reported that hepatocytic apoptosis was decreased by almost 90% in the Follistatin mice.
Follistatin may exhibit wound healing potential via possible stimulation of interfollicular stem cells, which may lead to increased hair growth. A clinical study was conducted where the potential of this synthetic protein formulation, Hair Stimulating Complex (HSC), was studied in subjects with hair loss.(14) A cohort of 26 subjects were presented with the peptide for a period of 52 weeks. Histopathological evaluation of the tissues reportedly showed improved hair growth after 52 weeks compared to the control group. Besides hair growth, researchers reported an apparent improvement in hair thickness and density by almost 13%.
Researchers suggested that when Follistatin-344 was presented to diabetic murine models, it appeared to lead to overexpression of the protein in the pancreatic cells, resulting in increased pancreatic beta cell (β-cell) mass, reduced glucose level, and overall reduction in diabetic symptoms.(15) β-cells are a population of cells in the pancreas primarily tasked with producing insulin to lower glucose levels. The data suggest that this β-cell proliferation is possibly due to the inhibition of SMAD2/3 signaling, a pathway typically activated by transforming growth factor-beta (TGF-β) superfamily members such as activin and myostatin, which are believed to be antagonized by Follistatin. This inhibition might indirectly activate the insulin-phosphoinositide 3-kinase (PI3K)-Akt pathway, posited as crucial for cell growth and survival, potentially contributing to increased β-cell mass and improved glucose homeostasis. The researcher’s comments suggest that β-cell specific overexpression of Follistatin may lead to several notable outcomes in the tested db/db mice: a substantial increase in pancreatic islet mass, enhanced β-cell proliferation indicated by co-immunofluorescent staining for Ki67 and insulin, and improved overall metabolic profiles including reduced hyperglycemia.
It is also noted that these actions were accompanied by changes in insulin signaling within the pancreas, as detailed by elevated insulin levels and enhanced activation of the insulin-PI3K-Akt signaling pathway. Moreover, the study posits that Follistatin may influence the expression of other regulatory proteins and genes within the pancreas. For instance, the increased mRNA levels of myostatin and activin, along with their inhibitors BAMBI and inhibin-α, suggest a complex interplay where Follistatin may act to modulate these signaling molecules, possibly leading to an enhanced β-cell proliferative environment.
Additionally, the study explores the potential modulation of betatrophin, a hormone implicated in β-cell proliferation. The researchers observed a significant increase in betatrophin expression in the Follistatin groups, which might be facilitated by the suppressed activity of activin and myostatin due to Follistatin action. This suggests that Follistatin may be enhancing β-cell proliferation not only through direct inhibition of negative growth regulators but also by promoting positive growth signals such as betatrophin.
Follistatin-344 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
Reviews
There are no reviews yet